http://rochester.technologypublisher.comBe the first to know about the latest inventions and technologies available from University of Rochesteren-USThu, 11 Mar 2010 10:18:54 GMTTue, 02 Mar 2010 14:15:41 GMThttp://blogs.law.harvard.edu/tech/rssdavid_englert@urmc.rochester.eduCopyright 2010, University of Rochesterhttp://rochester.technologypublisher.com/technology/4702Tue, 02 Mar 2010 14:15:41 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4702http://rochester.technologypublisher.com/technology/4701Tue, 02 Mar 2010 14:15:39 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4701http://rochester.technologypublisher.com/technology/4700Tue, 02 Mar 2010 14:15:39 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4700http://rochester.technologypublisher.com/technology/4699Tue, 02 Mar 2010 14:15:16 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4699http://rochester.technologypublisher.com/technology/4443 Applications: A wide range of approaches have now been applied following CNS injury to promote regenerative growth of both sensory and motor axons, with a particular focus on the transplantation of a variety of cell types, often in combination with other therapies. Such combinations have resulted in varying degrees of successful axon regeneration. This invention identifies a possible agent with high therapeutic potential, possibly providing some of the regenerative capacity of live cell transplants, while avoiding a number of the cell-based therapeutic obstacles. Advantages: The avail...Tue, 12 Jan 2010 06:53:00 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4443http://rochester.technologypublisher.com/technology/4233Wed, 09 Dec 2009 11:06:34 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4233http://rochester.technologypublisher.com/technology/4232Brief Description: Bone is a very dynamic organ as evidenced by the process of bone remodeling which relies on a delicate balance between bone formation and bone resorption and is orchestrated by osteoblasts (OB) and osteoclasts (OC). The coordinated interplay of OB and OC continuously remodels bone through highly regulated molecular and cellular events such that the entire human skeleton is replaced over the course of each decade of life. Disruption of the homeostatic balance of bone removal and replacement can manifest as pathologic bone loss observed in osteoporosis, periodontal dise...Wed, 09 Dec 2009 11:06:28 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4232http://rochester.technologypublisher.com/technology/4231Wed, 09 Dec 2009 11:06:09 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4231http://rochester.technologypublisher.com/technology/4230Wed, 09 Dec 2009 11:05:58 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4230http://rochester.technologypublisher.com/technology/4229Applications: Along with 6-1202, the present invention is directed to provide a chimeric protein capable of transduction into B cells for purposes of treating Class Switch Recombination and Somatic Hypermutation, both involved in antibody production and diversity, as well as other conditions such as B cell lymphoma. The present invention offers a chimeric protein (TAT-AID) which can be injected into animals or used to treat isolated B lymphocytes. The protein Activation Induced Deaminase (AID) can induce class switch recombination (CSR) and somatic hypermutation (SHM) that are essential...Wed, 09 Dec 2009 11:05:51 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4229http://rochester.technologypublisher.com/technology/4220Application: Automated Device for Asthma Monitoring (ADAM) is a device system that facilitates non-intrusive, continuous, valid and reliable monitoring of asthma symptoms. Asthma afflicts nearly 24 million in the US with 3,613 deaths /100k. There are 300 million asthmatics, and growing, worldwide. Healthcare cost for asthma is about $11.5 billion in the US. Advantages: Not being dependant on patient technique or compliance overcomes major difficulties faced when using other monitoring devices. Continuous automatic symptom monitoring, in real-life environments, with selective captur...Mon, 07 Dec 2009 12:37:22 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4220http://rochester.technologypublisher.com/technology/4219Application: Vasospasm occurs in up to 70% of patients with Subarachnoid hemorrhage (SAH) 4-14 days after the hemorrhage. This can lead to impaired cerebral auto-regulation and may progress to cerebral ischemia and infarction, requiring close monitoring and treatment for up to three weeks following the aneurysm treatment. SAH is a subset of stroke and occurs in 9 per 100k population with an annual cost in US of $1.75 billion. Approx. 15-20% of patients die before reaching the hospital and 25% die within 24hours with or without medical attention. Advantages: This unique device provid...Mon, 07 Dec 2009 12:37:14 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4219http://rochester.technologypublisher.com/technology/4218Mon, 07 Dec 2009 12:37:01 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4218http://rochester.technologypublisher.com/technology/4217Mon, 07 Dec 2009 12:36:46 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4217http://rochester.technologypublisher.com/technology/4216Mon, 07 Dec 2009 12:36:43 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4216http://rochester.technologypublisher.com/technology/4215Mon, 07 Dec 2009 12:36:24 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/4215http://rochester.technologypublisher.com/technology/3540Fri, 23 Oct 2009 11:31:46 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3540http://rochester.technologypublisher.com/technology/3515Tue, 20 Oct 2009 11:25:24 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3515http://rochester.technologypublisher.com/technology/3512Thu, 15 Oct 2009 12:06:14 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3512http://rochester.technologypublisher.com/technology/3511Application: A ventricular assist device (VAD) is an auxiliary blood circulation pump. It is implanted to assist the left, right or both ventricles to enhance circulation. The power source is worn externally by the patient with a cable going through the skin. The opening in the skin becomes a portal for serious infection which may also travel to the heart. Numerous attempts have been made over the years to power VADs transcutaneously. Almost all such attempts have been of some variation of electromagnetic energy transfer from a sending coil outside the body to a receiving coil inside ...Thu, 15 Oct 2009 12:06:09 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3511http://rochester.technologypublisher.com/technology/3510Thu, 15 Oct 2009 12:06:02 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3510http://rochester.technologypublisher.com/technology/3509Applications: Eosinophil-associated RNases (EARs) constitute a family of eosinophil RNases, whose secreted products possess anti-viral, anti-microbial, and antihelminthic enzymatic activity towards single-stranded RNAs. This implies that delivery of EARs to people at risk for lung disease can provide protection against viral infection. Intriguingly, EAR2 is a member of a larger family of highly homologous proteins with selective anti-pathogenic properties. For instance EAR2 (called eosinophil derived neurotoxin in humans) has strong anti-viral properties while EAR3 (called eosinophil c...Thu, 15 Oct 2009 12:05:56 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3509http://rochester.technologypublisher.com/technology/3365Thu, 27 Aug 2009 08:09:50 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3365http://rochester.technologypublisher.com/technology/3351Tue, 25 Aug 2009 09:54:40 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3351http://rochester.technologypublisher.com/technology/3334Wed, 19 Aug 2009 08:19:04 GMTdavid_englert@urmc.rochester.eduhttp://rochester.technologypublisher.com/technology/3334